DELFT, the Netherlands, 28 October 2026. The patent The claims of European patent EP 2 753 187 cover the use of a specific gut bacterium and protect a core application of Caelus’s platform. It stems from research at Amsterdam UMC and also covers the use of Caelus’s...
Financing round led by British Business Bank, and supported by leading international syndicate of investors Proceeds will advance Phase 2 clinical development of lead asset, MB310, in ulcerative colitis, a once-daily oral therapeutic designed to promote repair of the...
Anaerobutyricum soehngenii is the first live, gut-native bacterium of its kind to receive a positive EFSA safety opinion under the EU Novel Food Regulation, an important step toward reaching European consumers. DELFT, the Netherlands, 1 September 2026. Caelus welcomes...
EMIH member Mikrobiomik has announced that EUTEGRA® (MBK-01), its microbiota-based therapy for recurrent Clostridioides difficile infection (CDI), has been authorized in Spain under the National Spanish Substances of Human Origin (SoHO) framework (the SoHO Regulation...
Launched by EMIH and prepared by a committee of microbiome experts (members of EMIH), this first-of-its-kind bootcamp is designed as a practical, transdisciplinary and highly participative event. Over two days, industry leaders, product developers, academic...